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Thomas T. Provost and Rosemarie Watson
During the past 15 years, the clinical spectrum associated with the anti-Ro(SS-A) antibody response has been defined. Various
clinical presentations, including subacute cutaneous lupus erythematosus, the neonatal lupus syndrome, the Sjo¨gren’s syndrome/
lupus erythematous overlap syndrome, and primary Sjo¨gren’s syndrome, have been detected in association with the anti-Ro(SS-A)
response. The anti-Ro(SS-A) antibody response is associated with the HLA-DR2 and HLA-DR3 phenotypes. There is now a good
deal of evidence to suggest that many anti-Ro(SS-A) –positive HLA-DR3 women are genetically closely related, sharing in common
an enriched frequency of the HLA-DR3-linked B8, DQw2, and DRW52 phenotypes. DNA sequence studies have confirmed this
genetic relationship. These studies have led us to the following conclusions. (1) The HLA-DR2 and HLA-DR3 associations with
systemic lupus erythematosus and the HLA-DR3 association with Sjo¨gren’s syndrome are related to the anti-Ro(SS-A) antibody
response and not to the clinical disease expression. (2) HLA-DR3 anti Ro-positive female patients with first-degree Sjo¨gren’s
syndrome, subacute cutaneous lupus erythematosus, or Sjo¨gren’s syndrome, or who are asymptomatic, are immunogenetically
closely related even though the clinical presentations are strikingly different. All these HLA-DR3 anti-Ro(SS-A) antibody-positive
women are at risk to give birth to a child with the neonatal lupus syndrome. J Invest Dermatol 100:14S-20S, 1993
Several months before his death, Dr. James Gilliam and I (TTP) had
lunch at the annual Academy of Dermatology meeting. During this
lunch, Dr. Gilliam and I discussed the array of data being accumulated
in our laboratories that were clinically defining a large group of anti-
Ro(SS-A) antibody-positive patients. At that time, we discussed at
length the seemingly discordant clinical observations that had
detected the presence of anti-Ro(SS-A) antibodies in patients with
Sjo¨gren’s syndrome (SS) with no evidence of lupus erythematosus (LE);
in patients with subacute cutaneous lupus erythematosus (SCLE) and
acute onset lupus erythematosus who had no evidence of Sjo¨gren’s
syndrome; and in a group of asymptomatic women who gave birth to
children with the neonatal lupus erythematosus (NLE) syndrome. In
addition, anti-Ro(SS-A) antibody-positive patients had been described
under the rubric of antinuclear antibody (ANA) –negative systemic
lupus erythematosus and in association with homozygous C2 and C4
complement deficiencies.
The question that Dr. Gilliam and I pondered that day was
whether or not these patients were, indeed, related and, if so, how. As
we reviewed these data, we were both impressed by recently
published immunogenetic data, indicating that a large proportion of
anti-Ro(SS-A) antibody–positive lupus and Sjo¨gren’s syndrome patients
possessed either the HLA-DR2 and/or HLA-DR3 phenotypes [1-5].
The immunogenetic, clinical, and serologic data that now have
been accumulated demonstrate that a very significant number of
female anti-Ro(SS-A) antibody, HLA-DR3 patients with SCLE, NLE
infants, SS, and Sjo¨gren’s/lupus erythematosus (SS/LE) overlap syn-
drome are closely related. Much of these data have been generated in
collaboration with various colleagues including Frank Arnett, Elaine
Alexander, John Harley, Morris Reichlin, and Wilma Bias. Most recent
HLA studies by Drs. John Reveille and Frank Arnett, employing
restriction fragment length polymorphism, site-specific oligonucleo-
tides, and polymerase chain reaction (PCR), as well as DNA
sequencing technologies have confirmed and extended these observa-
tions. This is a summary of the clinical, serologic, and immunogenetic
data of these related HLA-DR3 anti-Ro(SS-A) –positive female patients.
These data were, in part, the subject of the Marion B. Sulzberger
Memorial Lecture given at the American Academy of Dermatology
meeting held in Atlanta, Georgia in December 1990.
ANTINUCLEAR ANTIBODY NEGATIVE
LUPUS ERYTHEMATOSUS
Our original studies on anti-Ro(SS-A) antibody-positive patients
involved a group of predominantly female patients whom we
identified as having widespread photosensitive cutaneous lupus
lesions and systemic features including arthralgias, arthritis, leukope-
nia, pleuropericarditis, and Raynaud’s phenomenon [6]. Six of the
original seven patients had intense, photosensitive malar lupus
dermatitis. The seventh patient had annular scarring (discoid) lesions
involving the face, arms, and trunk.
Serologically, these patients were most interesting because,
although they demonstrated classic cutaneous features of LE and
evidence of systemic involvement, all these patients initially failed to
demonstrate significant antinuclear antibody determinations, employ-
ing mouse liver as the ANA substrate. One patient, who had initially
presented with a photosensitive malar dermatitis, subsequently
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developed, 4 years later, a positive antinuclear antibody determination
and the presence of single-stranded DNA antibodies. Although these
patients initially failed to demonstrate significant antinuclear antibody
determinations, all possessed either anti La(SS-B) and/or Ro(SS-A)
antibodies.
These studies were subsequently expanded in a report of 66 ANA-
negative SLE patients (predominantly female) [7]. This study demon-
strated that 60 of 66 (91%) of these ANA-negative systemic lupus
erythematosus (SLE) patients had a malar dermatitis, and 52 of 66 (79%)
were photosensitive by history. Sixty-five of 107 (61%) ANA-positive
control lupus patients demonstrated a malar rash, and 21 of 107 (20%)
were photosensitive. Most important, only eight of the 66 ANA-negative
patients (12%) had renal disease in comparison to 45 of 107 (42%) of
ANA-positive lupus patients.
Serologically, 41 of the ANA-negative patients were anti-La(SS-B)
and/or anti-Ro(SS-A) antibody positive and, of the remaining 25 ANA-
negative SLE patients, 19 were anti-single-stranded DNA positive.
Anti–single-stranded DNA antibodies were detected in 20 of 41 (48%)
anti-La(SS-B) and/or anti-Ro(SS-A) antibody–positive patients. Thus,
although ANA negative, these patients did have serologic abnormalities.
Of the eight ANA-negative SLE patients with renal disease, seven
were anti-single-stranded DNA antibody positive by complement
fixation. Only one of these eight ANA-negative SLE patients was anti-
Ro(SS-A) antibody positive in the absence of anti-single-stranded
DNA, whereas three of these patients with glomerulonephritis
possessed anti–single-stranded DNA antibodies in the absence of
anti-Ro(SS-A) antibodies.
Preliminary investigations reported in this study indicated that
although these patients failed to demonstrate significant antinuclear
antibody titers employing mouse liver as a substrate, 66% of the sera
demonstrated nuclear staining when human KB cells were employed
as the antinuclear antibody substrate. These studies suggested that at
least part of the failure of these sera to demonstrate a positive
antinuclear antibody when mouse liver substrate was employed was
due to an antigenic deficiency in the mouse liver. This problem of
antigenic deficiency in the mouse compared to human substrates was
further explored in a study by Dore´ et al [8]. This study of 28 anti-
Ro(SS-A) antibody-positive patients failing to demonstrate a significant
ANA titer employing mouse liver confirmed our previous study and
demonstrated that 21 (75%) of the ‘‘ANA-negative’’ anti-RO(SS-A)
positive patients did indeed have ANA when various human cells were
employed as the ANA substrate.
Several new investigations have provided additional data regarding
ANA negativity in some anti-Ro(SS-A) antibody–positive patients. As
noted in Fig 1, there are a number of anti-Ro(SS-A) antibody-positive
patients who, by enzyme-linked immunosorbent assay (ELISA)
techniques, utilizing bovine Ro(SS-A) macromolecule as a source of
the antigen, fail to demonstrate significant anti-Ro(SS-A) titers [9].
However, if the same sera are then tested by ELISA utilizing the human
Ro(SS-A) macromolecule, significant titers are detected.
Utilizing classic absorption studies, Reichlin et al have demon-
strated that all human anti-Ro(SS-A) antibodies are directed against
unique human epitopes [10]. Their studies demonstrated that the
bovine Ro(SS-A) macromolecule was capable of absorbing some, but
not all, of the anti-Ro(SS-A) antibody activity from human sera,
whereas human Ro(SS-A) macromolecules were able to completely
absorb all human anti-Ro(SS-A) serum.
These studies demonstrated that anti-Ro(SS-A) antibodies are
directed against human epitopes, and these antibodies demonstrate
variable crossreactivity with Ro(SS-A) macromolecules from non-
human sources.
To gauge the potential magnitude of this problem, consider the fact
that in commercial laboratories that commonly employ non-human
sources of the Ro(SS-A) antigen it is not uncommon to have reports of
anti-La(SS-B) antibodies in the absence of anti-Ro(SS-A). In ours and
Reichlin’s experience, these anti-La(SS-B) antibody–positive patients,
when studied with human Ro(SS-A) antigen, have always demon-
strated the presence of anti-Ro(SS-A), antibody activity[9,11].
Additional studies by Boire et al have demonstrated that
the anti-Ro(SS-A) antibody is directed predominantly against con-
firma-tional epitopes [12]. Their studies utilizing native and SDS
polyac-rylamide gels with immunoblotting techniques demonstrated
that antibodies reactive against the native Ro(SS-A) macromolecule
frequently failed to react with the denatured Ro(SS-A) macromolecule.
Thus, all of these studies indicate that if non-human tissue is
employed as the antinuclear antibody substrate, a substantial
percentage of anti-Ro(SS-A) antibody-positive patients may fail to
demonstrate a significant antinuclear antibody titer. In addition to the
antigenic deficiency of the substrate as a reason for the failure to detect
a positive antinuclear antibody titer in anti-Ro(SS-A) antibody-positive
patients, the studies of Boire indicate that ANA negativity may
potentially occur due to the denaturing of the labile Ro(SS-A)
confirmational epitopes by fixation procedures employed in preparing
the substrate for the ANA determination.
CLINICAL STUDIES
Clinically, photosensitivity as well as widespread cutaneous lesions
were the dominant clinical features in this ANA-negative dermato-logic
and rheumatologic patient cohort group. Rothfield’s recent study has
also demonstrated that anti-Ro(SS-A)—positive rheumatology patients
demonstrate a great deal of photosensitivity. Ours and her group’s
studies indicate that as many as 90% of anti-Ro(SS-A) antibody-positive
patients are photosensitive [13]. Many give a spontaneous history of
burning through window glass. It is not uncommon for us to see
patients with a widespread phototoxic eruption without the classic
Figure 1. Comparison of anti-Ro(SS-A) antibody responses in a sensitive
‘‘sandwich’’ ELISA assay utilizing a bovine and human source for the Ro(SS-A)
antigen. Note that several negative sera on the bovine Ro(SS-A) ELISA have
significant titers on the human Ro(SS-A) ELISA. Note also the titers of all sera
are higher in the human versus the bovine Ro(SS-A) ELISA (from [9]).
VOL. 100, NO. 1, SUPPLEMENT, JANUARY 1993 ANTI-RO(SS-A) HLA-DR3-POSITIVE WOMEN 15S
features of lupus erythematosus, who upon testing demonstrate anti-
Ro(SS-A) antibodies. Many of these patients subsequently develop the
classic features of lupus erythematosus and some develop the classic
features of subacute cutaneous lupus erythematosus. Others remain
asymptomatic for as long as 5 years.
The morphology of the individual cutaneous lesions in anti-Ro(SS-
A)-positive patients are varied. In our initial studies, six of the seven
patients had a photosensitive dermatitis in the malar region (typical
butterfly distribution) [6]. In the follow-up study, malar dermatitis was
also a prominent feature, occurring in 37 of 41 anti-Ro(SS-A) antibody-
positive patients [7].
SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS
Complete review of the features of this very interesting subset of anti-
Ro(SS-A) antibody-positive exquisitely photosensitive lupus patients is
presented elsewhere in this issue. Our comments are relevant only to
the putative relationship between this subset and other anti-Ro(SS-A)
antibody-positive subsets that have been described. Comparison of
photographs that Jim Gilliam and Richard Sontheimer had taken of
their initial 27 subacute cutaneous lupus erythematosus (SCLE)
patients with those patients we were describing under the rubric of
ANA-negative SLE, indicated that a definite percentage but not all of
our patients were indeed the same as had been described under the
rubric of SCLE [14,15].
In recent years other investigators have questioned the validity of
the diagnoses of SCLE [16]. Studies carried out at our institution on 32
patients with the classic feature of SCLE indicate that approximately
15–20% of our outpatient lupus patient population, which encom-
passes predominantly a dermatologic patient population with some
patients with systemic lupus erythematosus, fall into this category [17].
Approximately 60% of these SCLE patients are anti-Ro(SS-A)
positive and the frequency of anti-Ro(SS-A) antibodies in our systemic
lupus population is 25–30%. We estimate that between 30 and 40% of
all anti-Ro(SS-A) antibody–positive lupus patients are classifiable as
SCLE. Our studies indicate that a significant proportion (44%) of these
SCLE patients may have sicca symptoms at the time of initial
presentation. The diagnosis of Sjo¨gren’s syndrome was confirmed by
minor salivary gland biopsies in six of 10 SCLE patients biopsied. The
serologic data of this group of patients are presented in Table I.
Several comments are in order regarding these serologic features.
I. Female SCLE patients had an 86% frequency of anti-Ro(SS-A)
positivity, whereas male SCLE patients had only a 30% positivity [17].
II. Unlike the group of patients previously described by us under the
rubric of ANA-negative SLE, this cohort of SCLE patients had a low
frequency of anti – single-stranded DNA antibodies [17]. This
serologic observation, plus the clinical data recounted above (i.e.,
absence of renal disease), indicates that the anti-Ro(SS-A)
antibody patients described as ANA-negative SLE were probably
more heterogeneous than this SCLE cohort.
III. Antiphospholipid antibodies that have been detected in as many
as 50% of SLE patients were detected in less than 10% of anti-
Ro(SS-A) antibody-positive SCLE patients. This negative relation-
ship between anti-Ro(SS-A) antibodies and the presence of
antiphospholipid antibodies reached statistical significance and
it has been our general impression that this relationship is
applicable to all anti-Ro(SS-A) antibody–positive lupus and
Sjo¨gren’s syndrome patients. Recent studies by Arnett et al have
demonstrated that the antiphospholipid antibody is frequently
associated with the HLA DR4 and DR5 phenotypes [18].
Approximately 70% of these patients are DQw7 positive.
IV. Serologic studies presented in Table I demonstrate a unique
association of the SCLE subset with the presence of anti-Ro(SS-A)
antibodies. You will note that there are negative statistical signi-
ficant associations of SCLE with other autoantibodies commonly
detected in lupus erythematosus.
NEONATAL LUPUS SYNDROME
The neonatal lupus syndrome (NLE) is characterized by the passage of
anti-La(SS-B) and/or anti-Ro(SS-A) antibodies from the mother to the
fetus [19,20]. The neonatal infant typically demonstrates either
annular polycyclic inflammatory lesions of SCLE or isolated congenital
heart block [21]. These two features appear to occur equally, and a
review of the literature strongly suggests that these two disease
manifestations generally occur independently, with only approxi-
mately 10% of infants demonstrating both [22].
Mothers of affected infants may subsequently give birth to another
child with the neonatal lupus syndrome. The affected infants of the
subsequent pregnancies will almost always have the same presenta-
tion as the initial sibling with the NLE syndrome. Thus, a family with
the NLE syndrome is characterized by one or more children with either
skin disease or isolated congenital heart block, but only occasionally
both clinical presentations. The reasons for this apparent specificity is
unknown at the present time. A likely candidate, however, would
appear to be the fine specificity of the anti-La(SS-B) or anti-Ro(SS-A)
antibody response.
In addition to the cutaneous lesions that frequently are similar to
those described in SCLE, and the isolated congenital heart block,
neonatal lupus infants may present with thrombocytopenia [23]
(recently Reichlin’s group has demonstrated the presence of Ro
antigens in human platelets) [24].
The development of the isolated congenital heart block in the
affected infants appears to be associated with the ontogeny (develop-
ment) of the neonatal heart. Studies of several hundred adult anti-
Ro(SS-A) – positive lupus and Sjo¨gren’s syndrome patients have
documented the rarity of conduction defects in adult systemic lupus
erythematosus and Sjo¨gren’s syndrome [25].
Recently we have developed an in vitro rabbit heart model to
explore the possible pathologic role of anti-Ro(SS-A) antibodies. We
have demonstrated that isolated cardiac papillary muscle from neonatal
but not adult rabbit hearts, perfused with anti-Ro(SS-A) antibodies but
not anti nDNA Sm, U1RNP, La, or cardiolipin antibodies, produced
prolongation of the repolarization phase of the cardiac action potential
[26]. Most recent in vitro studies reported in abstract form indicate that
40% of rabbit hearts perfused with human anti-Ro(SS-A)-positive sera
developed electrocardio-graphic evidence of complete heart block [27].
The neonatal lupus syndrome occurs predominantly in women
producing anti-La(SS-B) and/or anti-Ro(SS-A) antibodies. A few
mothers of neonatal lupus infants with cutaneous but not isolated
congenital heart block have anti-UlRNP antibodies in the absence
of anti-Ro(SS-A) antibodies [28]. The anti-Ro(SS-A)—positive NLE
mothers are predominantly HLA-DR3 positive [29]. The relationship of
Table I. Serologic Findings in 32 SCLE Patients [17]a
SCLE [17] SLE [47] p Value
Anti-Ro(SS-A) 19/32 (59%) 48/150 (32%) o0.05
Anti-La(SS-B) 4/32 (12%) 18/150 (12%) NS
nDNA Antibody 0/32 (0%) 42/150 (28%) o0.005
ssDNA Antibody 3/31 (10%) 134/150 (89%) o0.005
nRNP(UlRNP) Antibody 3/32 (9%) 51/150 (34%) o0.05
Sm Antibody 0/32 (0%) 26/150 (17%) o0.05
Anticardiolipin Antibody 3/31 (10%) 37/59 (63%) o0.005
aNS, not significant.
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the anti-Ro antibody response to the HLA-DR2 and HLA-DR3
phenotypes in the neonatal lupus syndrome is depicted in Table II.
Our studies and review of the literature suggest a negative relationship
between the presence of anti-Ro(SS-A) antibodies in a HLA-DR2-
positive mother and the neonatal lupus syndrome. For example, only
one of 31 anti-Ro(SS-A) – positive congenital heart block victims were
born of HLA-DR2 – positive mothers (Po0.05) [30].
Our studies as depicted in Table II indicate there is not a simple
relationship between the presence of HLA-DR3, the presence of anti-
Ro(SS-A) and La(SS-B) antibodies, and the development of the neonatal
lupus syndrome. There were no statistically significant differences in the
occurrence of these variables in mothers of neonatal lupus infants
compared to their frequency in anti-Ro(SS-A) –positive mothers of normal
infants. We conclude from these studies that other variables, perhaps
environmental (e.g., in utero occult viral infection etc.), are important in
the development of neonatal lupus erythematosus.
Clinically, these anti-La(SS-A) – and/or anti-Ro(SS-A) – positive
mothers may present with classic features of lupus erythematosus or
Sjo¨gren’s syndrome. Approximately 40%, however, are asymptomatic
at the time of the birth of their affected infant [22].
SJO¨GREN’S SYNDROME
Sjo¨gren’s syndrome is an inflammatory disease characterized by
infiltrates composed of lymphocytes, plasma cells, and histiocytes
involving the lacrimal and minor salivary glands as well as other organs,
including the thyroid, pancreas, kidney, muscles, and skin. The disease
is thought to affect approximately 3,000,000 people in the U.S.A.,
making it equal to, or second to, rheumatoid arthritis in frequency of
occurrence. Sjo¨gren’s syndrome, like lupus erythematosus, occurs
predominantly in women (9:1). Clinically, the overwhelming majority
of these patients present with dryness of the eyes and mouth and
patients also frequently complain of dryness of the vagina. Other
Sjo¨gren’s syndrome patients present with extraglandular manifestations,
including thyroid disease, pulmonary disease, interstitial nephritis,
myositis, chronic active hepatitis, primary biliary cirrhosis, peripheral
and central nervous system disease, and cutaneous vasculitis.
Our group has detected the presence of two histopathologic
different types of vascular insults occurring in small and medium-sized
skin arteries [31]. Tsokos et al have confirmed this observation and
have described leukocytoclastic, lymphocytic vasculitis, acute necro-
tizing angitis, and endarteritis obliterans involving small and medium-
sized arteries in Sjo¨gren’s syndrome [32]. Our studies have also
demonstrated the occurrence of peripheral and central nervous system
disease in Sjo¨gren’s syndrome patients with vasculitis [33]. We suspect
the nervous system manifestations represent a vasculo-pathy of small
blood vessels feeding peripheral nerves as well as the central nervous
system. Although the clinical features of these observations are beyond
the scope of this review, these observations have, in part, been
confirmed and extended [34].
Our studies suggest the existence of more than one disease process
that produces an inflammatory infiltrate of the lacrimal and minor
salivary glands of the oral mucosa [9].This hypothesis has emerged
from the realization that those SS patients presenting themselves to
dermatologists with either urticarial-like vasculitic lesions or palpable
purpura of the lower extremities as well as those predominantly
hospitalized SS patients on a rheumatology service demonstrate the
presence of anti-Ro(SS-A) antibodies in a frequency of approximately
45% (gel double diffusion) [34]. Furthermore, employing a very
sensitive ELISA assay, as many as 90% of this rheumatology SS patient
cohort with many extragrandular manifestations have been detected to
be anti-Ro(SS-A) antibody positive [36].
In contrast, recent studies in our laboratory examining the sera of
minor salivary gland (lip) biopsy-positive, predominantly non-hospi-
talized Sjo¨gren’s syndrome patients referred from allergists, gyneco-
logists, otolaryngologists, general internists, dermatologists, as well
as rheumatologists, utilizing a very sensitive sandwich Ro(SS-A) ELISA
assay, demonstrated a frequency of only 30% [9]. These data also
suggest that referral centers may have a definite selection bias with
regard to the detection of Sjo¨gren’s syndrome patients with prominent
extraglandular manifestations and anti-Ro(SS-A) positivity.
SJO¨GREN’S SYNDROME/LUPUS ERYTHEMATOSUS
OVERLAP PATIENTS
During the course of our studies, we have seen a group of patients who
have either first developed Sjo¨gren’s syndrome and then subsequently
developed the photosensitive cutaneous lesions of SCLE, or vice versa
[37]. Many of these patients have had a disease process that has
persisted for decades. These patients, in addition to SS, frequently
demonstrate cutaneous vasculitis, pulmonary, interstitial nephritis,
hypothyroidism, and peripheral and central nervous system disease.
We suspect that these patients have also been described under the rubric
of ‘‘late onset’’ lupus erythematosus because their clinical features are
quite similar, if not identical, to those we have described [38].
As so often happens in medicine, a chance observation prompted
us to reinvestigate all anti-Ro(SS-A) patients and to propose a hypo-
thesis to be tested. We propose that many of these anti-Ro(SS-A)
– positive HLA-DR3 women with varied clinical presentations (i.e.,
ANA-negative SLE, SCLE, NLE in mothers, primary SS, and the SS/LE
overlap) are all related and are, in fact, different clinical expressions of
the same disease process occurring over a three- to four-decade period
of time [36]. The observation that stimulated this hypothesis was that
three of our original 17 SS/LE overlap patients had given birth to
children with the neonatal lupus syndrome [36].
IMMUNOGENETIC STUDIES
The hypothesis for a major role of genetic factors in the development
of autoimmunity in LE and SS is based primarily on family and twins
studies. Approximately 10–12% of first- and second-degree relatives of
LE as well as SS patients are also similarly affected [39–41]. Other
family studies have demonstrated among first- and second-degree
relatives a collective aggregation of definable autoimmune diseases as
well as autoantibody formation [42,43].
In one study, monozygotic twins have been demonstrated to have a
57% concordance of lupus erythematosus, compared to an approx-
imate 5% in dizygotic twins [44]. Although these studies amply
demonstrate a possible role for genetic factors in the pathogenesis of
autoimmune diseases, they also amply demonstrate by their lack of
100% concordance that other factors, perhaps environmental, are also
important.
Table II. Relationship of Neonatal Lupus Mothers to
Anti-Ro(SS-A) – Positive Mothers of Normal Infants
Ro and
La
Ro
only HLA-DR3
HLA-DR2 (+)
HLA-DR3 ()
Number
(%)
Number
(%)
Number
(%)
Number
(%)
Mothers/CHBa 6/10 (60) 4/10 (40) 6/9 (67) 1/9 (11)
Mothers/LDb 11/21 (52) 10/21 (48) 14/19 (73) 3/9 (16)
Ro Mothers
(normal infants)
3/14 (21) 11/14 (78) 7/14 (50) 5/14 (36)
P Value NS NS NS NS
aCHB, congenital heart block.
bLD, lupus dermatitis.
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Classic HLA serologic studies have demonstrated a statistically
significant increased frequency of the HLA-DR2 and HLA-DR3
phenotypes in SLE, and the HLA-DR3 phenotype in SS [3,45,46].
The relative risk of these associations, however, is small [2–3]. Our
studies in LE and SS have indicated that approximately 90% of anti-
Ro(SS-A) antibody-positive lupus and Sjo¨gren’s syndrome patients
have either the HLA-DR2 and/or the HLA-DR3 phenotype [3–5]. In
fact, our studies indicate that if one subtracts the anti-Ro(SS-A)
antibody-positive patients from the total systemic lupus erythematosus
and Sjo¨gren’s syndrome cohorts, one removes the statistically
significant association of HLA-DR2 and -DR3 from systemic lupus
erythematosus and the HLA-DR3 association with Sjo¨gren’s syndrome.
These studies have led us to postulate that in these two
autoimmune diseases, SLE and SS, the HLA associations are with the
anti-Ro(SS-A) antibody response.
Additional studies have indicated a very significant association of
the HLA-DR3 but not the HLA-DR2 phenotype with the anti-La(SS-B)
antibody response [47]. These studies have also indicated that the
HLA-DR3 anti-Ro(SS-A) antibody response is associated with a much
greater titer than the HLA-DR2 anti-Ro(SS-A) antibody response [36].
Further serologic studies suggest that the highest titer anti-Ro(SS-A)
and La(SS-B) antibody responses were associated with DQwl/DQw2
heterozygosity [48].
A good deal of evidence has been accumulated indicating that
various anti-Ro(SS-A) antibody-associated lupus subsets are associated
with the HLA-DR3 phenotype (Table III). Subacute cutaneous lupus
erythematosus anti-Ro(SS-A) female patients appear to have a
statistically significant association of both the HLA-DR2 and -DR3
phenotype [17] (Table IV). Thus, although these patients appear
clinically and serologically similar, they differ immunogenetically,
suggesting the existence of two different anti-Ro(SS-A) antibody-
positive patient populations with the same clinical presentation.
Unfortunately, no HLA studies were performed on the ANA-negative
lupus population that demonstrated a 60% frequency of anti-Ro
antibodies. However, clinical and serologic data suggests that this too
is a heterogeneous population; undoubtedly a number of these
patients are similar to those described under the rubric of SCLE.
HLA studies of NLE mothers demonstrate a prominent association
with HLA-DR3 and a negative association with HLA-DR2 (Table III)
[29,30]. A similar striking association with HLA-DR3 and a negative
association with HLA-DR2 has also been seen in our anti-Ro(SS-A)
positive women with the SS/LE overlap syndrome [49], These data
suggest that these latter two anti-Ro(SS-A) antibody subsets are much
more homogeneous immunogenetically than those patients described
as having SCLE or ANA-negative lupus erythematosus.
HLA studies in Sjo¨gren’s syndrome have demonstrated the
association of both HLA-DR2 and -DR3 with the anti-Ro(SS-A)
– positive patients [3]. However, only the HLA-DR3 association
reaches statistical significance. These data also suggest that among the
anti-Ro(SS-A) –positive SS patients, there is heterogeneity with regards
to an immunogenetic background, but these patients are perhaps more
homogeneous than those seen with ANA-negative and subacute
cutaneous lupus erythematosus.
When we examined a series of phenotypes in linkage disequili-
brium with HLA-DR3 (i.e., B8, DQw2, and DRW52) we found that, in
comparison to normal controls, these series of phenotypes (perhaps
representing a haplotype, although this can only be surmised because
family studies were not done) occurred in a significant population of
anti-Ro(SS-A) antibody women with SCLE, NLE in mothers, SS/LE
overlap patients, and first-degree SS patients, providing further support
for the immunogenetic relationship of these various anti-Ro(SS-A)
– positive subsets [3,17,49,50] (see Table V).
Most recent data by Arnett and Reveille et al have explored the
anti-Ro(SS-A) antibody response using restriction fragment length
polymorphism, site-specific oligonucleotides with polymerase chain
reaction, and DNA sequencing [51,52]. Their studies have confirmed
and greatly extended serologic HLA studies that had demonstrated a
strong association of HLA-DR2 and -DR3 with the anti-Ro(SS-A)
antibody response. These studies indicate that the HLA-DR2 and -DR3
phenotypes are not the primary associations with the anti-Ro(SS-A)
antibody response. It now appears that HLA-DQ alleles involving the
HLA-DQa and -DOb chains promote the anti-Ro(SS-A) antibody
response. Their studies have demonstrated that all DQa (DQA1)
alleles of anti-Ro(SS-A) and La(SS-B) antibody-positive patients possess
Table III. Comparison of HLA Phenotypes Between Ro(SS-A) – Positive SCLE Patients (n=22) Versus NLE Mothers
(n=21) and SS/LE Overlap Patients [17]
SCLE NLE SS/LE
HLA Phenotypes Number % Number % P Value Number % P Value
B8 9 43 17 81 2.4 102 11 69 NSa
DR2 11 52 4 19 (0.07) 2 12 2.6102
DR3 13 59 17 81 NS 13 76 NS
DQW1 25 68 11 55 NS 10 59 NS
DQW2 13 59 18 90 NS 13 76 NS
DQW1/W2 9 41 9 45 NS 7 41 NS
DRW52 18 82 20 95 NS 17 100 NS
aNS, not significant.
Table IV. Frequency of HLA-DR2 and HLA-DR3 in
Subacute Cutaneous Lupus Erythematosus Patients
Reported in Literature (Adapted from [17])
Number of Patients Ro(SS-A)+ HLA-DR2 HLA-DR3
27 [1] 60% NDa 77%
8 [49] 100% 13% 75%
13 [53] 60% ND 82%
13 [54] 46% 54% 50%
32 [17] 59% 45% 48%
aND, not determined.
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a glutamine residue at position 34 of the outer domain. (Previous
studies, as noted above, indicate these anti-Ro and La-positive patients
are predominantly HLA-DR3 positive [47].) In addition, all of the DQb
(DQB1) alleles associated with the Ro(SS-A) and La(SS-B) antibody
responses possessed a leucine residue at position 26. These amino
acids map to the floor of the major histocompatibility peptide binding
cleft, and are in the second hypervariable regions of the HLA DQ
molecule (Fig 2). These associations were seen in both anti-Ro(SS-A)-
positive Caucasian and black patients with SLE and SS. Those patients
demonstrating heterozygosity for combinations of these DQA1 and
DQB1 alleles demonstrated the highest titers. It also should be noted
that 100% of all patients with La(SS-B) and/or Ro(SS-A) antibodies had
one or more of these DQA1 or DQB1 alleles.
Thus, what was speculation in a conversation that Jim Gilliam and I
had shortly before his death has now been amply documented to be
true. In a brief period of time, less than 15 years, we have seen a
spectrum of disease encompassing anti-Ro(SS-A) – positive patients
with LE and SS described. The immunogenetic data have now
conclusively demonstrated that some of these patients are, indeed,
closely related. These studies further indicate that these patients’
disease process is very dynamic and the clinical presentations vary
greatly. The earliest manifestation may be a phototoxic reaction in an
otherwise asymptomatic woman. Those anti-Ro(SS-A) -positive wo-
men bearing the HLA-DR3 phenotype are at risk to give birth to
children with the neonatal lupus syndrome. Their disease process with
time will demonstrate the features of lupus erythematosus, most
commonly SCLE or SS, or they will develop features of both diseases
(SS/LE overlap). The disease process, although at times producing
significant morbidity, frequently is present for three to four decades.
The reason for the marked variation in phenotypic expression is
unknown, although the skin manifestations at times are strikingly
influenced by sun exposure. The work of Reveille and Arnett now
suggests that these anti-Ro(SS-A) HLA-DR3 women may differ from
other anti-Ro(SS-A) antibody patients by the presence of one or more
allelic difference residing either in the DQA1 or DQB1 chain. From
the data thus far presented, it is unclear which allelic differences are
associated with the DQwl (DQW6 subtype), which is in linkage
disequilibrium with HLA-DR2, and which allelic differences are
associated with DQW2.1, which is in linkage disequilibrium with
HLA-DR3 (DRW17). It is predictable that further analysis will indeed
demonstrate this difference and establish the molecular immunoge-
netic basis for this group of anti-Ro(SS-A) antibody HLA-DR3-positive
women who have been described under the rubrics of ‘‘ANA-
negative’’ SLE, SCLE, first-degree SS, NLE in mothers, and women
with the SS/LE overlap syndrome.
However, the greater challenge will be to determine the complex
immunologic mechanisms that produce the varied tissue damage in
these HLA-DR3, anti-Ro(SS-A) – positive syndromes and the variables
that influence these different clinical expressions.
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